Circulation, 146, 657-672 Circulation : an official journal of the American Heart Association / ed.-in-chief Ephraim Donosco 146(9), 657-672 (2022). doi:10.1161/CIRCULATIONAHA.121.057807 Hagström, E, Steg, P G, Szarek, M, Bhatt, D L, Bittner, V A, Danchin, N, Diaz, R, Goodman, S G, Harrington, R A, Jukema, J W, Liberopoulos, E, Marx, N, McGinniss, J, Manvelian, G, Pordy, R, Scemama, M, White, H D, Zeiher, A M, Schwartz, G G, ODYSSEY OUTCOMES Investigators & Bøttcher, M 2022, ' Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab ', Circulation, vol. 146, no. 9, pp. 657-672 . https://doi.org/10.1161/CIRCULATIONAHA.121.057807 Circulation, vol 146, iss 9 Circulation, 146, 9, pp. 657-672 Circulation, Philadelphia : Lippincott Williams & Wilkins, 2022, vol. 146, iss. 9, p. 657-672 Circulation, 146(9), 657-672. LIPPINCOTT WILLIAMS & WILKINS
Europace, 23(6):euab012, 887-897. Oxford University Press Europace, 23, 887-897 Europace, 23, 6, pp. 887-897 Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 23(6), 887-897. Oxford University Press EP Europace, 23(6), 887-897. OXFORD UNIV PRESS Europace, 23(6), 887-897. OXFORD UNIV PRESS Europace Europace, 23(6), 887-897. Oxford University Press Verstraelen, T E, van Barreveld, M, van Dessel, P H F M, Boersma, L V A, Delnoy, P-P P H M, Tuinenburg, A E, Theuns, D A M J, van der Voort, P H, Kimman, G P, Buskens, E, Hulleman, M, Allaart, C P, Strikwerda, S, Scholten, M F, Meine, M, Abels, R, Maass, A H, Firouzi, M, Widdershoven, J W M G, Elders, J, van Gent, M W F, Khan, M, Vernooy, K, Grauss, R W, Tukkie, R, van Erven, L, Spierenburg, H A M, Brouwer, M A, Bartels, G L, Bijsterveld, N R, Borger van der Burg, A E, Vet, M W, Derksen, R, Knops, R E, Bracke, F A L E, Harden, M, Sticherling, C, Willems, R, Friede, T, Zabel, M, Dijkgraaf, M G W, Zwinderman, A H & Wilde, A A M 2021, ' Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death ', Europace, vol. 23, no. 6, pp. 887-897 . https://doi.org/10.1093/europace/euab012 Europace : European pacing, arrhythmias, and cardiac electrophysiology, 23(6), 887-897. Oxford University Press EP Europace, 23(6), 887-897. Oxford University Press
Lancet Diabetes & Endocrinology r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname The Lancet Diabetes & Endocrinology Volume 7 Issue 8 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Lancet diabetes & endocrinology ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tunon, J, White, H D, Zeiher, A M, Schwartz, G S, Steg, P G, Schwartz, G G, Steg, P G, ODYSSEY OUTCOMES Committees and Investigators, Clemmensen, P, Gislason, G, Nielsen, P K, Davidsen, F, Andersen, D, Jeppesen, J & Videbæk, L 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA Lancet Diabetes and Endocrinology, 7(8), 618-628. ELSEVIER SCIENCE INC